ADTXHIGH SIGNALFINANCIAL10-K

ADTX experienced a dramatic operational contraction with revenue collapsing to near-zero levels while operating cash outflows substantially worsened despite reduced R&D spending.

The near-complete revenue collapse combined with worsening cash burn despite cost-cutting efforts suggests severe operational distress. The company appears to be burning through cash reserves while generating minimal revenue, raising serious questions about business viability and funding runway.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

ADTX's financial position deteriorated markedly with revenue falling to just $3K from $134K while operating cash outflows substantially worsened to $25.7M despite meaningful reductions in R&D expenses. The company reduced total assets and liabilities by approximately half, suggesting significant restructuring or asset liquidation, while the dramatic revenue decline indicates core business operations have essentially ceased. The combination of near-zero revenue generation and accelerating cash burn presents a critical liquidity challenge.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-97.6%
$134K$3K

Revenue declined 97.6% — significant demand weakness or market share loss warrants investigation.

Current Assets
Balance Sheet
+91.1%
$2.0M$3.8M

Current assets grew 91.1% — improving short-term liquidity or inventory/receivables build.

Accounts Receivable
Balance Sheet
-89.4%
$408K$43K

Receivables declined — improved collection efficiency or conservative revenue recognition.

R&D Expense
P&L
-70.7%
$10.9M$3.2M

R&D spending cut 70.7% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
-53.3%
-$16.8M-$25.7M

Operating cash flow fell 53.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Inventory
Balance Sheet
-48.7%
$11K$6K

Inventory drawn down 48.7% — strong sell-through or deliberate destocking; watch for supply constraints.

Total Assets
Balance Sheet
-48.6%
$32.1M$16.5M

Total assets contracted 48.6% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
-47.8%
$23.4M$12.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-47.3%
$23.9M$12.6M

Liabilities reduced 47.3% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+29.8%
-$27.9M-$19.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
As of March 30, 2026, the registrant had 904,469 and 904,468 shares of common stock, $0.001 par value per share, issued and outstanding, respectively.
Overview and Mission We believe the world needs and deserves a new approach to innovation that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations reach people who need them most.
The Company was founded with a mission of redefining how health innovations are discovered, developed, and deployed transforming a highly centralized industry into a socially owned and guided ecosystem to advance human well-being.
Since then, we expanded our portfolio of innovations and subsidiaries, and we continue to evaluate a variety of promising health innovations.
ADI-100, the first product candidate based on the ADI platform, is designed to tolerize against an antigen known as glutamic acid decarboxylase ( GAD ), which is implicated in type-1 diabetes (T1D), psoriasis, and in many autoimmune diseases of the CNS and has been successfully tested in several preclinical models (e.g., skin grafting, psoriasis, and T1D).
+7 more — sign up free →
REMOVED
As of March 28, 2025, the registrant had 1,159,201 and 1,159,200 shares of common stock, $0.001 par value per share, issued and outstanding, respectively.
The 2024 Proxy Statement will be filed with the Securities and Exchange Commission (the SEC ) within 120 days after the end of the fiscal year to which this report relates.
federal government; we do not expect to pay dividends in the foreseeable future; we have issued a significant number of restricted stock awards, restricted stock units, options and warrants and may continue to do so in the future.
The vesting and, if applicable, exercise of these securities and the sale of the shares of common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock; future sales or issuances of substantial amounts of our common stock, including, potentially as a result of future acquisitions or strategic transactions, including the transactions with Evofem Biosciences, Inc.
could result in significant dilution; while we have entered into a Merger Agreement with Evofem Biosciences, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →